Safety Study of TPX-121 on Nasolabial Folds

Phase 1

Recruiting

• Conditions: Nasolabial Fold, Hypoplastic
• Interventions: Biological: TPX-115(allogeneic fibroblasts)

• Registration Number: NCT06533540
• Lead Sponsor: Tego Science, Inc.

Brief Summary

Nasolabial folds augmentation is possible through dermal filler and botulinum toxin, however, safety issues are existed as well as efficacy. Therefore, there is a need for a safer procedure for nasolabial folds correction. This study (Project No. TPX-121) assesses the safety of allogeneic fibroblasts (TPX-115) on nasolabial folds. The safety endpoint is dose-limiting toxicity (DLT). In addition, exploratory endpoints are the improvement of nasolabial folds in Wrinkle Severity Rating Scale (WSRS) at week 4 and 12, change in WSRS and Wrinkle Severity Scale (WSS) at week 4 and 12, and overall appearance improvement rate in Global Aesthetic Improvement Scale (GAIS) at week 4 and 12.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-07-29
• Study First Submitted QC: 2024-07-29
• Study First Posted: 2024-08-01
• Status Verified: 2024-12
• Study Start: 2024-12-11
• Last Update Submitted: 2024-12-18
• Last Update Posted: 2024-12-20
• Primary Completion: 2026-03
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

1. Be 19 years old or older
2. Have confirmed nasolabial folds severity equal to or more than grade 3 evaluated by WSRS and WSS at face to face evaluation.
3. Have unsatisfied or very unsatisfied nasolabial folds.
4. Voluntarily sign the informed consent for participation in the study.

Exclusion Criteria

Current disease and medical history

1. Inflammatory and infectious skin diseases, unhealed wounds and scars (e.g. Keloids), or benign tumor on nasolabial folds.

2. Chronic skin diseases (e.g. Psoriasis, Atopic dermatitis).

3. Genetic diseases that affect fibroblasts or collagen (e.g. Achondroplasia, Osteogenesis imperfecta).

4. Autoimmune diseases.

5. Active hepatitis B or C (However, in the case of simple carriers or hepatitis B, except when the antiviral agent was stably taken for 6 months prior to screening).

6. Human immunodeficiency virus (HIV) positive.

7. Coagulopathy.

8. History of malignant tumors within the last 5 years.

9. Anaphylaxis or severe combined allergy

10. Have allergies to bovine proteins or gentamicin.

11. Acute or chronic infectious diseases.

12. Severe heart diseases (e.g. Myocardial infarction, Heart failure), severe liver diseases (e.g. Cirrhosis, Liver failure), or severe renal diseases (e.g. Kidney failure).

13. Hypersensitivity to amide-based local anesthetics (However, those who agree not to use local anesthetics can register).

    Prohibited drugs and treatments.

14. Administered systemic corticosteroids within 12 weeks prior to screening or is scheduled to be administered for at least 2 weeks during the study.

15. Treated cell therapy or stem cell therapy within 1 year prior to screening.

16. Surgical procedures or surgeries such as fillers or fat grafting on facial part within 1 year prior to screening.

17. Surgical procedures or surgeries of permanent fillers on facial part prior to screening.

18. Surgical procedures or surgeries of botulinum toxin injection or face lift surgery on facial part within 6 months prior to screening.

19. Planned facial cosmetic surgery to improve nasolabial folds during the study.

    Laboratory inspection

20. Those who fall under the following figures during screening. 1) White blood cell < 4.5x10^3/ul and > 11.0x10^3/ul 2) Platelet count < 100,000/mm^3 3) Hemoglobin < 9g/dL

    Other

21. Disagree to take pictures of nasolabial folds

22. Be pregnant, breastfeeding, planning pregnancy or unwilling to use of contraceptice.

23. Have participated in other clinical trials and recevied investigational products/devices within 30 days of this study.

24. Be deemed inadequate for the study by investigators(e.g. A person with severe asymmetry in the lower echocardiogram).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
middle dose	TPX-115(allogeneic fibroblasts)	-
high dose	TPX-115(allogeneic fibroblasts)	-
low dose	TPX-115(allogeneic fibroblasts)	-

Primary Outcome Measures

Name	Time	Method
Dose-limiting toxicity	Week 4	The number of subjects evaluated grade 3 or higher adverse drug reactions according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Trial Locations

Locations (1)

Kyungpook National University, School of Medicine; 🇰🇷 Daegu, Jung-gu, Korea, Republic of